Similarly, Yamamura et al. have developed an exon-skipping therapeutic strategy that prevents progression of kidney failure in a Col4a5 mutant mouse (Yamamura et al., 2020), which may be available in future for patients with truncating COL4A5 mutations. This evidence concerns the gene COL4A5 and kidney failure.